Pharmaceuticals
Akeso's Cadonilimab (PD-1/CTLA-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China
* Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing * China's first immunotherapy bi-specific antibody approved for marketing * A phase III trial of Cadonilimab combined with platinum-based chemotherapy +/- bevacizumab for the first-line treatment ...
2022-06-29 20:14
2797
BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures
NEW YORK, June 29, 2022 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client,BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement withGenFleet Therapeutics, Inc., an immuno-oncology focused biopharmaceutical company b...
2022-06-29 20:00
4366
Positive data from the clinical phase I MAD study with AlzeCure's Alzheimer's project NeuroRestore ACD856
STOCKHOLM, June 29, 2022 /PRNewswire/ -- AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced th...
2022-06-29 19:32
2448
Seegene to pave way for PCR testing at local clinics with EU-approved multiplex test and fully automated PCR solution
SEOUL, South Korea, June 29, 2022 /PRNewswire/ -- Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx) company, has obtained EU approval for its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay that is compatible with the company's fully automated 'AIOS' (All-in-One System). This is ...
2022-06-29 19:00
2834
Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications
SAN FRANCISCO and SUZHOU, China, June 29, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-06-29 08:00
4073
NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe
- Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potential milestones and double-digit royalties on net pro...
2022-06-29 00:53
3905
OME Health, a UK-based DIGITAL health company, announces the launch of a novel health and nutrition coaching platform on the heels of a new funding round
LONDON, June 28, 2022 /PRNewswire/ -- OME Health recently closed a new funding round led by Gen-tech Investments, with the participation of global pharmaceutical company Bayer AG, leading athletics company ASICS Ltd., and existing investors. The company also launched a B2B nutrition and health c...
2022-06-28 21:56
2826
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
* Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - * Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - * Palleon receives u...
2022-06-28 21:50
4593
Seegene develops PCR test to detect monkeypox virus
* Assay targets monkeypox virus and can deliver results in 90 minutes * Company swiftly rolls out product using its automated assay development system * "Seegene will strive to make accurate tests for emerging viruses to help prevent future pandemics" SEOUL, South Korea, June 28, 2022 /PRN...
2022-06-28 19:00
3565
Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection
-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an expected enrollment of 30 subjects HANGZHOU, China and SHAOXING, China, June 28, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the first subject has been ...
2022-06-28 18:11
3784
Sanofi Enters into a Partnering Agreement with Health2Sync
Paving the Way for Digital Therapeutics in Diabetes TAIPEI and TOKYO, June 27, 2022 /PRNewswire/ -- Sanofi K.K. (Head office: Shinjuku-ku,Tokyo; President: Takahiko Iwaya; hereinafter "Sanofi") and Health2Sync. (Head office: Taito-ku,Tokyo; CEO: Ed Deng) have entered into a partnering agreement ...
2022-06-28 11:00
2882
IFN Neurologic and MetaCell Partner to Launch the IFN Neurologic Affiliate Program
CAMBRIDGE, Mass., and PERTH, Australia, June 28, 2022 /PRNewswire/ -- Summary The Institute of Functional Neuroscience, a world leading treatment and rehabilitation centre utilising the latest technologies in neuroplasticity research, and MetaCell, an innovative life science software company spe...
2022-06-28 09:05
3226
Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases
SUZHOU, China, June 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it was selected ...
2022-06-28 08:00
3283
JOYSBIO offers SARS-COV-2 Antigen Rapid Test that detects Omicron subvariants BA.4 and BA.5
TIANJIN, China, June 27, 2022 /PRNewswire/ -- As the SARS-COV-2 Omicron subvariants BA.4 and BA.5 make their way across the EU and the US, Joysbio is able to give people the power to administer a rapid test for themselves at home. The Joysbio Coronavirus Antigen Rapid Test Kit can effectively det...
2022-06-27 15:30
4409
Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss
--Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for functional cure of CHB at oral session of EASL ILC 2022 on June 25, 2022, Beijing Time --The Phase IIb clinical trial results further demonstrated the potential of ASC22+NAs treatment as a functional cu...
2022-06-27 08:11
4204
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and o...
2022-06-27 08:00
5147
Congratulations to Dragon Boat Biopharmaceutical from Sanyou Biopharmaceuticals on the NMPA acceptance of the CLDN 18.2/CD47 bsAb clinical trial application
SHANGHAI, June 25, 2022 /PRNewswire/ -- On June 15, 2022, Dragon Boat announced that its IND application of the innovative anti-CLDN 18.2/CD47 bi-specific antibody (bsAb) injection (R&D code: BC007) was officially accepted by National Medical Products Administration (NMPA) under the acceptance nu...
2022-06-26 08:00
4508
Sanyou Biopharmaceuticals forged strategic partnership with Dragon Sail Pharmaceutical to upgrade integrated innovative antibody drug R&D
SHANGHAI, June 24, 2022 /PRNewswire/ -- Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, aCDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture servic...
2022-06-25 08:00
5456
Daewoong Pharmaceutical begins multinational phase 2 clinical trial for DWN12088, a new drug for idiopathic pulmonary fibrosis
- U.S. Food and Drug Administration (FDA) approved the IND for the phase 2 clinical trial for patients with idiopathic pulmonary fibrosis - Daewoong Pharmaceutical to start a multinational phase 2 clinical trial for DWN12088 in September SEOUL, South Korea, June 24, 2022 /PRNewswire/ -- Daewoong...
2022-06-24 21:00
4354
MGI Wins Company Innovation of the Year at 2022 Globee® Awards for Advanced COVID-19 Response Efforts
SHENZHEN, China, June 24, 2022 /PRNewswire/ -- MGI, a company committed to being a world-leading life science innovator, has been awarded a Silver Globee® in the 14th Annual 2022 Golden Bridge Business and Innovation Awards® for its innovative COVID-19 pandemic control and response efforts worldw...
2022-06-24 00:17
3883
Week's Top Stories
Most Reposted
HLB Customers Can Now Scan & Pay in China with HLB QR Pay
[Picked up by 294 media titles]
2026-10-22 22:35
SALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
[Picked up by 282 media titles]
2026-10-19 13:18
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia's Automotive Sector
[Picked up by 276 media titles]
2026-10-21 15:00
TCL Zhonghuan Powers India's Energy Transition with PV Innovations at REI Expo 2026
[Picked up by 273 media titles]
2026-10-23 21:52
DayOne Supports NVIDIA DSX POD Reference Design, Advancing Standardized Infrastructure for AI
[Picked up by 271 media titles]
2026-10-22 11:55Most Read
Hi3D V1.0 Goes Open Source: The First Production-Validated Open-Source AI 3D Model
2026-10-23 23:30
21995
Home 3D Printers are More Accessible Than Ever This Black Friday with Bambu Lab
2026-10-22 17:00
20312
BeautyPlus Web Launches Halloween Photo Booth With Behind-the-Scenes Video Export
2026-10-23 01:00
18305
